Organovo Logo (2 Color Med-Res-082117).png
Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals
09 août 2018 16h05 HE | Organovo, Inc.
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019 Lead IND program for Alpha-1-antitrypsin deficiency (“A1AT”) expected to commence IND-enabling...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Announces Appointment of Steven G. Hughes, M.D. as Chief Medical Officer
01 août 2018 08h05 HE | Organovo, Inc.
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that Steven G. Hughes has been named Chief Medical Officer.  Dr. Hughes is an industry...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Results
19 juil. 2018 08h05 HE | Organovo, Inc.
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, August 9, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Reports Fiscal Fourth-Quarter and Full-Year 2018 Results; Company Announces Key Goals for Fiscal-Year 2019
31 mai 2018 16h05 HE | Organovo, Inc.
- Lead Investigational New Drug (“IND”) program for Alpha-1-antitrypsin deficiency (“A1AT”) received FDA’s orphan drug designation and is on track for commencing IND-enabling studies in fiscal 2019 -...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results
14 mai 2018 08h05 HE | Organovo, Inc.
SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, May 31, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the...
Organovo Logo (2 Color Med-Res-082117).png
Organovo to Present New Preclinical Data for Its Liver Therapeutic Tissue IND-Track Programs at the World Advanced Therapies and Regenerative Medicine Congress
10 mai 2018 08h05 HE | Organovo, Inc.
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that it will present new preclinical data showing the strong functionality of its liver...
Organovo Logo (2 Color Med-Res-082117).png
Organovo and Samsara Sciences Partner with New Manufacturing USA Institute
03 mai 2018 08h05 HE | Organovo, Inc.
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced it has joined a new public-private Manufacturing USA initiative, the Advanced...
Organovo Logo (2 Color Med-Res-082117).png
Organovo to Present at 2nd Annual NASH Summit
24 avr. 2018 08h05 HE | Organovo, Inc.
SAN DIEGO, April 24, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that it will present at the 2nd Annual NASH Summit in Boston, Ma. on Tuesday, April...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Achieves Key Development Milestones for Its Liver Disease and Intestinal Tissue Models
16 avr. 2018 08h05 HE | Organovo, Inc.
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that along with its collaborators, it has achieved several breakthrough capabilities...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Presents Data on Modeling Liver Disease Using 3D Bioprinted Human Liver Tissue at The International Liver Congress™
12 avr. 2018 08h05 HE | Organovo, Inc.
SAN DIEGO, April 12, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today presented data on modeling non-alcoholic fatty liver disease (“NAFLD”) using its 3D bioprinted...